Русский
Sulodexide: meta-analysis of the treatment of diabetic nephropathy and literature review
DOI: https://dx.doi.org/10.18565/pharmateca.2023.12.12-20
M.S. Novikova, O.M. Koteshkova, M.B. Antsiferov
1) Endocrinological Dispensary of the Moscow Healthcare Department, Moscow, Russia; 2) Central State Medical Academy of the Administrative Department of the President of the Russian Federation, Department of Therapy, Cardiology and Functional Diagnostics with a Course in Nephrology, Moscow, Russia
Objective. Discussion of the results of a meta-analysis that was conducted to evaluate the effectiveness of sulodexide treatment of diabetic nephropathy.
Results. Sulodexide is a heterogeneous group of sulfated glycosaminoglycans, which mainly consists of low molecular weight heparin. Clinical studies have shown that sulodexide is able to reduce urinary albumin excretion in patients with type 1 and type 2 diabetes mellitus (DM). A meta-analysis was conducted to summarize the clinical results of all prospective clinical studies on the clinical efficacy and safety of sulodexide in diabetic patients with nephropathy. In general, sulodexide therapy was accompanied by a significant decrease in urinary protein excretion. In the sulodexide group, 220 patients (17.7%) achieved a reduction in albumin excretion of at least 50% compared with 141 (11.5%) in the placebo group. The odds ratio in patients with therapeutic efficacy between the sulodexide and placebo groups was 3.28 (95% confidence interval: 1.34–8.06; P=0.01).
Conclusion. These data indicate the renoprotective effect of sulodexide in diabetic patients with micro- and macroalbuminuria and may be the basis for the treatment of diabetic nephropathy with sulodexide, in particular, the prevention of end-stage renal disease associated with DM [1].
Results. Sulodexide is a heterogeneous group of sulfated glycosaminoglycans, which mainly consists of low molecular weight heparin. Clinical studies have shown that sulodexide is able to reduce urinary albumin excretion in patients with type 1 and type 2 diabetes mellitus (DM). A meta-analysis was conducted to summarize the clinical results of all prospective clinical studies on the clinical efficacy and safety of sulodexide in diabetic patients with nephropathy. In general, sulodexide therapy was accompanied by a significant decrease in urinary protein excretion. In the sulodexide group, 220 patients (17.7%) achieved a reduction in albumin excretion of at least 50% compared with 141 (11.5%) in the placebo group. The odds ratio in patients with therapeutic efficacy between the sulodexide and placebo groups was 3.28 (95% confidence interval: 1.34–8.06; P=0.01).
Conclusion. These data indicate the renoprotective effect of sulodexide in diabetic patients with micro- and macroalbuminuria and may be the basis for the treatment of diabetic nephropathy with sulodexide, in particular, the prevention of end-stage renal disease associated with DM [1].
About the Autors
Corresponding author: Maria S. Novikova, Cand. Sci. (Med.), Associate Professor at the Department of Therapy, Cardiology and Functional Diagnostics with a Course in Nephrology, Central State Medical Academy of the Administrative Department of the President of the Russian Federation; Nephrologist, Endocrinological Dispensary of the Moscow Healthcare Department, Moscow, Russia; citrus7474@mail.ru; ORCID: https://orcid.org/0000-0003-1320-0565
Similar Articles
